RELATED STUDY
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies
Key Findings: This meta-analysis concludes that the current pre-clinical and clinical studies available overall support that cannabis can improve the effect of opioids and also reduce the amount of opioids needed in the treatment of acute pain. Further studies are needed to evaluate dosing and specific populations that would likely benefit the most from the addition of cannabis therapies for pain relief.
Type of Study: Meta-analysis
Study Sample Size: 90
Study Result: Positive
Study Location(s): Australia, Canada
Year of Pub: 2022
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Tetrahydrocannabinol (THC), CP-x Synthetic Cannabinoids, AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Cannabinoid (unspecified), Endocannabinoid (unspecified), Pharma THC, Pharma THC:CBD, Delta-8-THC, Cannabidivarin (CBDV)
Phytocannabinoid Source: Unspecified
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB1, CB2, GPCR 55, Opioid Receptor Mu , Opioid Receptor Delta, Opioid Receptor Kappa, GPCR
